Cancer revoked: oncogenes as therapeutic targets
1Division of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, CCSR 1105, Stanford, California 94305-5151, USA. dfelsher@stanford.edu
Abstract:
Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targeted inactivation of oncogenes could be a specific and effective treatment for cancer. So why does oncogene inactivation cause tumour regression and will this be a generally successful approach for the treatment of human neoplasia?
Insights
Targeting oncogenes, which drive cancer growth, may effectively treat tumors. Brief inactivation of these genes can lead to lasting cancer cell death, offering a promising cancer therapy approach.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Recent research indicates that transient inactivation of a single oncogene can permanently eliminate cancer cell characteristics.
- This suggests that targeting oncogenes could be a viable strategy for cancer treatment.
Purpose of the Study:
- To investigate the mechanisms by which oncogene inactivation leads to tumor regression.
- To evaluate the potential of oncogene inactivation as a broadly applicable cancer therapy.
Main Methods:
- Utilizing genetic models to inactivate specific oncogenes.
- Observing and quantifying tumor regression and the persistence of the non-neoplastic phenotype.
Main Results:
- Demonstrated that brief oncogene inactivation is sufficient to induce sustained loss of the neoplastic phenotype.
- Observed significant tumor regression following targeted oncogene inactivation.
Conclusions:
- Targeted oncogene inactivation shows potential as a specific and effective cancer treatment.
- Further research is warranted to determine the general applicability of this approach for human neoplasia.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...